Next Article in Journal
Augmentation of Antidiabetic Activity of Glibenclamide Microspheres Using S-Protected Okra Powered by QbD: Scintigraphy and In Vivo Studies
Next Article in Special Issue
Bone Tissue Engineering in the Treatment of Bone Defects
Previous Article in Journal
Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer
 
 
Article

Article Versions Notes

Pharmaceuticals 2022, 15(4), 490; https://doi.org/10.3390/ph15040490
Action Date Notes Link
article xml file uploaded 18 April 2022 14:43 CEST Original file -
article xml uploaded. 18 April 2022 14:43 CEST Update https://www.mdpi.com/1424-8247/15/4/490/xml
article pdf uploaded. 18 April 2022 14:43 CEST Version of Record https://www.mdpi.com/1424-8247/15/4/490/pdf
article html file updated 18 April 2022 14:45 CEST Original file -
article html file updated 2 August 2022 19:31 CEST Update https://www.mdpi.com/1424-8247/15/4/490/html
Back to TopTop